Results 31 to 40 of about 6,071 (199)
Journal of Infection in Developing Countries, 2021 Introduction: Respiratory syncytial virus (RSV) is one of the most important childhood infections. Objective: To evaluate the effectiveness and safety of palivizumab immunoprophylaxis in preterm infants at a high risk of severe respiratory syncytial ...
Juan Gabriel Piñeros +11 more
doaj +1 more source
Italian Journal of Pediatrics, 2009 Introduction The aim of this study was to assess the cost-utility of palivizumab versus no prophylaxis in the prevention of respiratory syncytial virus infection among high-risk preterm infants.
Ravasio Roberto +2 more
doaj +1 more source
iNew Medicine, Volume 2, Issue 2, June 2026.This illustration integrates key concepts covered in the review, including high‐risk populations, viral structure, host entry factors, the replication cycle, and licensed antibody‐based prevention strategies. ABSTRACT Respiratory syncytial virus (RSV) is a negative‐sense RNA virus belonging to the genus Orthopneumovirus within the family Pneumoviridae.
Zekai Cheng +3 more
wiley +1 more source
Palivizumab coverage rates among moderate-to-late preterm infants in Korea: a nationwide cross-sectional study [PDF]
Epidemiology and HealthOBJECTIVES Since October 2016, Korea has implemented a national reimbursement program for palivizumab aimed at moderate-to-late preterm (MLPT) infants born between 32 0/7 weels and 35 6/7 weeks of gestation during the respiratory syncytial virus (RSV ...
Seungyeon Kim +3 more
doaj +1 more source
Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants
Pediatric Pulmonology, Volume 61, Issue 6, June 2026.ABSTRACT Introduction Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and hospitalization in infants. Since 2023, France has implemented two preventive strategies aimed at reducing RSV burden: long‐acting monoclonal antibody nirsevimab and RSV vaccine for pregnant women, the latter becoming available from September 2024.
Marine Tarizzo +7 more
wiley +1 more source
Journal of Microbiology, Immunology and InfectionBackground: Respiratory syncytial virus (RSV) infection may induce asthma and allergic sensitisation. RSV immunoprophylaxis can reduce the severity of RSV infections. However, the effects of RSV immunoprophylaxis on allergic sensitisation remains unclear.
Li-Ching Fang, Jen-Yu Wang
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2021 Down syndrome (DS) is an independent risk factor for severe respiratory syncytial virus (RSV) infection. Palivizumab – passive immunization for RSV – is the only pharmacological measure for preventing severe disease.
Masato Takeuchi, Koji Kawakami
doaj +1 more source
Acta Paediatrica, Volume 115, Issue 6, Page 1258-1265, June 2026.ABSTRACT Aim Respiratory syncytial virus (RSV) infection is a leading cause of paediatric hospitalisations. This study describes annual RSV‐hospitalisation burden of disease, by gestational week of delivery, age and sex among children aged 0–17 years of age in Sweden, for the period 2010/11–2021/22.
Kristian Bolin +4 more
wiley +1 more source
Journal of Clinical Ultrasound, Volume 54, Issue 4, Page 915-923, May 2026.This study is to assess the predictive value of the modified lung ultrasound score (mLUS) for late respiratory diseases in premature infants born before 32 weeks of gestation. It is recommended that the use of mLUS scoring be promoted in clinical practice for the early screening of high‐risk preterm infants.
Shuang Zheng +4 more
wiley +1 more source
Improving Palivizumab Compliance Through a Pharmacist-Managed RSV Prevention Clinic
, 2017 OBJECTIVESPalivizumab is a monoclonal antibody approved for the prevention of serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk pediatric patients.
Jennifer W. Chow +5 more
core +1 more source